Patients treated with biological drugs (anti-TNF-alpha, anakinra, canakinumab, roactemra) did not show a statistically significant difference among the different groups of patients, in terms of vaccination against flu and/or COVID-19 (Table 4). The gene discussed is TNF; the disease is COVID-19.